Overview

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2027-07-01

Target enrollment:

Participant gender:

Summary

A Randomized, Multicenter Study Investigating Efficacy and Safety of anti-PD-1/PD-L1-treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer. The objective of the phase 2 study is to induce a meaningful Progression-Free Survival (PFS) benefit in patients with stage IIIB/IIIC or stage IV NSCLC by treating with anti-PD-1/PD-L1 treatment and UV1 vaccination versus anti-PD-1/PD-L1 treatment alone.

Phase:

Phase 2

Details

Lead Sponsor:

Vestre Viken Hospital Trust

Collaborators:

Alesund Hospital
Haukeland University Hospital
Helse Fonna
Helse Forde
Helse Nord-Trøndelag HF
Helse Stavanger HF
Oslo University Hospital
St. Olavs Hospital
University Hospital of North Norway
University Hospital, Akershus

Treatments:

Sargramostim